Skip to main content

Most Popular

Consensus Statements on Vitamin D

The “Controversies in Vitamin D” International Conference has published their proceedings on vitamin D metabolism, assessment, actions, and supplementation. Interestingly, optimal levels of 25-hydroxy vitamin D (25(OH)D) are still being debated. 

Read Article

JAK or TNF Inhibitor as First Drug for Rheumatoid Arthritis?

Medpage Today

A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic drugs had failed, a pragmatic head-to-head trial found.

Read Article

2023 EULAR classification criteria for hand osteoarthritis

A EULAR consensus group has established classification criteria for overall hand osteoarthritis (OA) and its subtypes (interphalangeal OA and thumb base OA).

The criteria require two mandatory criteria to be met:

Read Article

Upside/Downside of Steroids in Lupus Nephritis

A systematic review of randomized clinical trials of patients with biopsy-proven lupus nephritis (LN) demonstrates both the benefits and harms to early glucocorticoid (GC) regimens on lupus outcomes. 

Read Article

Biomarkers Predictive of a Deucravacitinib Response in Psoriatic Arthritis

A phase II trial demonstrating the clinical efficacy of deucravacitinib, a TYK2 inhibitor, in psoriatic arthritis (PsA) suggests specific biologic effects identified by biomarkers may predict clinical responses.

Read Article

Role of Diet in Gout Risk

Diet has long been influential in gout care and risks. A large cohort study has shown that plant-based diets may reduce the risk of developing gout.

This prospective study assessed the risk of developing incident gout based on consumption of healthy and unhealthy plant-based diets.

Read Article

Gangsin: 갱신 Korean: refresh, renew, updated

                     “New beginnings are often disguised as painful endings” - Taoist proverb

Read Article

Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis

A single center study demonstrates that biologic treatment of psoriasis (PsO) significantly reduces the likelihood of psoriatic arthritis (PsA) development; suggesting a role for more aggressive treatment of PsO. 

Read Article

Legal (Not So) Merry-Go-Round of Alendronate Atypical Fractures

Dr. Gregory Curfman, MD (Executive editor of JAMA) writes on the chronological legal progress of a lawsuit stemming from rare instances of atypical femoral fractures associated with bisphosphonate (alendronate) use.

Read Article

"Don't You Know Who I am?" (5.17.2024)

Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This week's question: can we prevent gout, ILD or psoriasis?

Read Article

The Window of Opportunity (5.24.2024)

Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week: blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?

Read Article

Cannabis Use is Common, But is it Safe?

Two current JAMA reports suggest that cannabis use is not only common, but that if heavily used may increase mortality rates.

Read Article

EULAR 2024 - Day 1 Report

Wednesday was Day One at EULAR 2024 in Vienna. While the day was a slow start, the poster halls and auditoriums quickly filled with thousands of rheumatologists, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1. 

Read Article

Humira Clobbers Biosimilars in Battle for Part D Coverage

Medpage Today

Just about every Medicare Part D prescription drug plan on offer this year covers the original version of adalimumab (Humira), whereas only about half will pay for any of the several biosimilar versions currently approved, researchers found.

Read Article

ACR’s Run at Goliath (PCPs) (5.31.2024)

Dr. Jack Cush reviews the journal reports and articles from this past week on RheumNow.com.  The ACR (and Cush) address their new website designed to educate PCPs and APPs - what do you think?

Read Article

No Great Options for Treating VEXAS

MedPage Today

For patients with the auto-inflammatory disease VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed.

Read Article

Window of Opportunity in Psoriatic Arthritis

The Dutch southwest Early psoriatic arthritis (PsA) cohort study has demonstrated that the earlier the referral and diagnosis of PsA, the better the outcome. 

Read Article

Antacids can Diminish Bone Density

EurekAlert!

Proton pump inhibitors (PPIs), a specific class of antacid drugs, are among the most widely used medications of all. They are frequently prescribed to many groups of patients, including those with rheumatism.

Read Article

Hypertension not associated with High NSAID Doses in AxSpA

Medscape

At the recent SPARTAN annual meeting in Cleveland, Dr. Jose Meade-Aguilar reported that amongst axial spondyloarthritis (axSpA) patients receiving nonsteroidal anti-inflammatory drugs (NSAIDs), there was no difference in the risk for hypertension when comparing those on high vs.

Read Article

Is Cannabis Safe? (6.7.2024)

Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!

Read Article